SANTA CLARA, Calif. / May 22, 2023 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced that the company will participate in Q&A sessions at the Jefferies and Goldman Sachs healthcare conferences. Below are details of each session.
Jefferies Global Healthcare Conference
Mike McMullen, Agilent President and CEO
Wednesday, June 7
9:00 – 9:25 a.m. ET / 6:00 – 6:25 a.m. PT
Goldman Sachs 44th Annual Global Healthcare Conference
Bob McMahon, Agilent CFO
Tuesday, June 13
1:00 – 1:40 p.m. ET / 10:00 – 10:40 a.m. PT
Those interested in listening to the live or recorded sessions can access them from the Events section of Agilent’s investor relations website. Recordings will be available for 90 days.
About Agilent Technologies
Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.
Last Trade: | US$108.05 |
Daily Change: | -28.05 -20.61 |
Daily Volume: | 408,960 |
Market Cap: | US$30.860B |
April 24, 2025 March 20, 2025 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load